12.34 0.00 (0.00%)
After hours: 4:15PM EDT
|Bid||12.38 x 1200|
|Ask||12.75 x 800|
|Day's Range||12.33 - 12.77|
|52 Week Range||6.18 - 17.57|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.47|
MCK earnings call for the period ending March 31, 2020.
Change Healthcare today unveiled InterQual 2020, the latest edition of the company's flagship clinical decision support solution.
Greenlight Capital Fund recently released its Q1 2020 Investor Letter, a copy of which you can download below. The fund posted a return of -21.5% for the quarter, underperforming its benchmark, the S&P 500 Index which returned -19.60% in the same quarter. You should check out Greenlight Capital’s top 5 stock picks for investors to […]
Change Healthcare today introduced an online COVID-19 research environment for qualified public and private healthcare organizations.
Change Healthcare (Nasdaq: CHNG) will release fourth-quarter fiscal 2020 financial and operating results after market close on Wed., June 3, 2020.
Change Healthcare is making its Connected Consumer Health™ interoperability APIs available at no charge to help payers comply with CMS mandate.
Kaufman, Hall & Associates, LLC ("Kaufman Hall"), a leading provider of enterprise performance management (EPM) software, data and management consulting solutions, and Change Healthcare (Nasdaq: CHNG), a leading independent healthcare technology company, today announced that Kaufman Hall has acquired Change Healthcare's Analytics Explorer, Performance Manager and other data solutions, collectively referred to as Connected Analytics, and combined them with Kaufman Hall Software.
Buy low, sell high — that’s the mantra for making money in the stock market, right?And the first part of the process sounds simple enough: Find a cheap stock with a low price-to-earnings ratio, buy it — then wait for it to rise in price.Problem is, some stocks are cheap for a reason. No matter how cheaply you buy them, there’s no guarantee they’ll go up. So how do you improve your chances of finding a winner?TipRanks uses a system called Smart Score. Crunching data on Wall Street sentiment, buying activity by insiders and hedge funds, and other factors — including, yes, low P/E — TipRanks assigns each stock a smart score rating indicating a level of confidence that it will outperform the market, on an easy to understand scale of 1 to 10.Those stocks at the tippety top of the scale score a perfect 10 — and over the last nine years they’ve outperformed the average S&P 500 stock by nearly 50%.We’ve pulled up three "perfect 10" stocks that tick every box, to find out why they are poised to make gains even in today’s difficult market environment.Change Healthcare (CHNG)The first "perfect 10" name on today’s list is Change Healthcare, a software company that provides solutions for analysis, connectivity, communication, payment, and workflow optimization for healthcare providers. Change’s products connect patients, payers, and providers in the health system. In the current pandemic situation, a company that connects the data dots for the healthcare system should find itself in demand.Change reported its fiscal third quarter results in February, its third since going public, and beat the earnings estimates by 10%. EPS came in at 33 cents, and revenue was $808.2 million.In recent weeks, Change has taken concrete steps to makes its data services useful for the healthcare industry generally, opening a COVID-19 Updates and Resources hub, and a CARES Act Advisory resource hub, to make information available to interested parties who will be impacted by governmental measures taken to combat the epidemic.5-star analyst Steven Halper, of Cantor Fitzgerald, is impressed by CHNG’s prospect and policies, especially given the pandemic situation, writing, “While COVID is likely to be a near-term headwind to its financial results, the company has launched a number of solutions aimed at addressing customers' COVID-related issues... We maintain our view that CHNG should continue to increase its market share due to its differentiated data-driven and network-based approach.”In line with his bullish view, Halper gives the stock a Buy rating with a $20 price target that suggests an impressive upside of 96%. (To watch Halper’s track record, click here)Credit Suisse analyst Jailendra Singh agrees that CHNG is a stock to buy. In comments on the stock, Singh points out the company’s favorable debt position and the positive forward outlook for profits after the epidemic, when the healthcare system restarts elective procedures and sees a consequent surge in demand for data and payment processing services.Singh’s Buy rating is backed by a $16 price target, which while less bullish than Halper’s still points toward 57% upside growth.Looking at the Smart Score factors, CHNG receives a Strong Buy consensus rating, and investor sentiment over the past month shows rising interest in this stock. Shares have dropped in price this year, pulled down by the general bear market, giving investors a chance to buy low. CHNG is priced at $10.22, and the average price target of $16.71 indicates a 68% upside potential for the coming 12 months. (See Change stock analysis at TipRanks)Hannon Armstrong (HASI)Next up is Hannon Armstrong, a financial services company focused on climate change. Where some just talk about the need to support green initiatives, Hannon Armstrong puts its money where its mouth is, investing in, and funding ventures in, energy efficiency, renewable energy, and sustainable infrastructure. As of December 2019, the company was managing more than $6 billion in assets.While such green initiatives frequently have a reputation as money sucking black holes, Hannon has selected its investments well and consistently returned quarterly profits. In recent weeks, Hannon has announced a $150,000 cash donation for COVID-19 relief efforts in its home state of Maryland. The company also raised its dividend by a half cent, to an even 34 cents quarterly. The new dividend makes the annualized payment $1.36 and went into effect this month. At 5.2%, the yield is significantly higher than the market average, and simply blows away Treasury bonds. Hannon has a 7-year history of dividend reliability.On the financial front, Hannon has announced bond offers, of $400 million in 6% Green Bonds and of $350 million in Senior Unsecured Notes. Issuing debt on that scale while during such a volatile time for markets is a bold move – but also shows a high level of corporate confidence.Christopher Van Horn, reviewing the stock for B. Riley FBR, writes, “We estimate that COVID disruptions could be less volatile than what is being priced into shares and given the financial nature of the biz model, we think pipeline remains on track. While we would not be surprised to see certain projects pushed out, the pipeline of over $2.5B is significant.”In line with his upbeat view of Hannon’s prospects, Van Horn rates the stock a Buy. His $42 price target implies an upside of 59%. (To watch Van Horn’s track record, click here)Oppenheimer analyst Noah Kaye agrees. In fact, he gives HASI shares an identical $42 price target. Backing the bullish views, Kaye writes, “We believe appetite for green bonds remains relatively strong and will be looking for pricing terms on the notes to validate our view. While we do believe a persistence of current macroeconomic conditions could stress components of the balance sheet portfolio, we expect earnings to be relatively resilient given the portfolio's diversification…”Hannon’s ’10’ Smart Score comes from its Strong Buy consensus rating along with rising stock purchases by both investors and insiders. Hannon has received 5 Buy ratings in recent weeks, opposed to a single Hold. With a share price of $26.46 and an average target of $35.83, the stock shows a robust 12-month upside potential of 35%. It’s a solid outlook, for a green stock that has maintained sound investment profile. (See Hannon’s stock analysis at TipRanks)Air Products and Chemicals (APD)Last on our list for now is Air Products and Chemicals, a provider of chemicals and gasses for industrial use. Based in Allentown, Pennsylvania, APD remains an important Rust Belt industrial employer, and brings significant revenues to its region. In its fiscal Q1 (ending in December 2019), the company registered a top line of $2.254 billion, up 1% year-over-year.Like Hannon above, APD pays out a dividend – and has kept its dividend payments reliable for the last 20 years. The payout ratio, 62%, shows a commitment sharing profits with investors, while the yield of 2.6% is noticeably higher than the ~2% yield found among S&P stocks. APD has raised its quarterly dividend payment 3 times in the past three years.Covering the stock for Wells Fargo, 5-star analyst Michael Sison is clearly impressed. His Buy rating is backed by a $265 price target, indicative of a 20% upside potential. (To watch Sison’s track record, click here)In his report on the stock, Sison writes, “While risks of COVID-19 and significant drop in oil prices still persist, we believe APD has enough levers to drive EPS growth in FY20 and FY21 despite the likelihood of slower economic growth… In our view, the key driver to growth is a strong backlog of projects coming on stream in the next couple years, which should support over 50% of growth… We believe APD is among the better positioned chemical companies in CY1Q, with industrial gas companies generally being much more resilient relative to other chemical companies…”Air Products’ '10' Smart Score shows positive points almost across the board. The stock is rated a Strong Buy, and insiders have been buying up the shares in the last three months, as some of the major hedge funds. At $207, and with an average price target of $252, the stock shows potential for 21% growth this year. The Strong Buy consensus rating is based on a 12 to 2 Buy/Hold split among 14 recent reviews. (See Air Products stock analysis at TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Change Healthcare (Nasdaq: CHNG) announces the appointment of Steven Martin as executive vice president of enterprise technology.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Change Healthcare launches a CARES Act advisory hub to help providers gain access to emergency federal funding made available through the CARES Act.
Change Healthcare launches COVID-19 resource to help providers and payers maintain administrative, financial, and operational stability during crisis.
Based on its recent analysis of the North American blockchain technology market for healthcare billing and claims adjudication, Frost & Sullivan recognizes Change Healthcare with the 2019 North American Enabling Technology Leadership Award. The Intelligent Healthcare Network™ with Blockchain technology can help expedite claims processing while lowering administrative costs for the healthcare industry. Helping to enhance communication and data exchange across the medical claims management lifecycle, the technology will streamline and track interactions and events accurately and helps to relay information reliably to all stakeholders in the shortest time possible.
Change Healthcare (CHNG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Change Healthcare will present virtual, on-demand versions of its educational and interactive sessions originally planned for the HIMSS20 conference.
Change Healthcare Inc. today announced the successful completion of the split-off of McKesson’s ownership interest.
McKesson Corporation (NYSE:MCK) today announced the completion of the split-off of PF2 SpinCo, Inc. ("SpinCo"), which held McKesson’s interest in Change Healthcare LLC ("Change Healthcare") and which was merged with and into Change Healthcare Inc. (NASDAQ:CHNG) ("Change") through a "Reverse Morris Trust" transaction. The closing of the merger followed the previously announced expiration of McKesson’s exchange offer. As a result of the merger, participating McKesson stockholders will receive one share of Change common stock in exchange for each whole share of SpinCo common stock they received in the exchange offer.
McKesson Corporation (NYSE:MCK) today announced that its previously announced offer to stockholders to exchange their shares of McKesson common stock on a per-share-basis for 11.4086 shares of PF2 SpinCo, Inc. ("SpinCo") common stock expired at 11:59 p.m., New York City time, on March 9, 2020, and, based on preliminary results, the exchange offer was oversubscribed. The exchange offer to split-off SpinCo, which holds McKesson’s interest in Change Healthcare LLC ("Change Healthcare"), is part of McKesson’s agreement with Change Healthcare Inc. (NASDAQ:CHNG) ("Change") to merge SpinCo with and into Change (the "Merger").
Change Healthcare announces a change to its fireside chat time at the Barclays Global Healthcare Conference 2020--March 12, at 9:00 a.m. EDT.
Leading drug distributor stocks remain sensitive to ongoing opioid settlement negotiations. Here are crucial technical levels to watch.
Change Healthcare's (CHNG) third-quarter fiscal earnings benefit from solid performance across the segments - Software and Analytics and Network Solutions. However, decline in revenues remains a woe.